Association between apolipoprotein E polymorphism and macroalbuminuria in patients with non-insulin dependent diabetes mellitus

Nephrology Dialysis Transplantation

Volumn 14, Issue 9, 1999, Pages 2144-2149

  Ha, Sung Kyu ^b,c   Park, Hong Su ^b   Kim, Kyung Wook ^b   Kim, Seung Jung ^a   Kim, Do Hun ^a   Kim, Jung Ho ^b   Lee, Ho Yung ^b   Han, Dae Suk ^b  

^a Ajou University School of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

Apolipoprotein E; Macroalbuminuria; Normoalbuminuria; Polymorphism

Indexed keywords

ALBUMIN; APOLIPOPROTEIN E; CREATININE; DNA; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE DURATION; DNA POLYMORPHISM; FEMALE; GENDER; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ALBUMINURIA; ALLELES; APOLIPOPROTEINS E; CARRIER PROTEINS; DIABETES MELLITUS, TYPE 2; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROTEIN ISOFORMS; REFERENCE VALUES;

EID: 0032814895     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/14.9.2144     Document Type: Article

References (25)

1. Mulec H, Johnson SA, Bjorck S. Relation between serum cholesterol and diabetic nephropathy. Lancet 1990; 335: 1537-1538
2. Harris KP, Purkerson ML, Yates J, Klahr S. Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome. Am J Kidney Dis 1990; 15: 16-23
3. Krolewski AS, Warram JH, Christlieb AR. Hypercholesterolemia: A determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int 1994; 45[Suppl 45]: S125-S131
4. Keane WF, Kasiske BL, O'Donnell MP. Lipids and progressive glomerulosclerosis: A model analogous to atherosclerosis. Am J Nephrol 1988; 8: 261-271
5. Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993; 21: 573-592
6. Komatsu T, Kanatsu K, Ochi H, Kita T, Doi T. Lipoprotein glomerulopathy with a new apolipoprotein E phenotype. Am J Kidney Dis 1995; 25: 952-953
7. Rall SC, Weisgraber KH, Mahley RW. Human apolipoprotein E. The complete amino acid sequence. J Biol Chem 1982; 257: 4171-4178
8. Wilson PW, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia and coronary heart disease: The Framingham Offspring Study. JAMA 1994; 272: 1666-1671
9. Diamond JR. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int 1991; 39 [Suppl 31]: S29-S34
10. Mahley RW. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 1988; 240: 622-630
11. Brown MS, Goldstein JL. Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic. J Clin Invest 1983; 72: 743-747
12. Paik YK, Chang DJ, Reardon CA, Davies GE, Mahley RW, Tailor JM. Nucleotide sequence and structure of the human apolipoprotein E gene. Proc Natl Acad Sci USA 1985; 82: 3445-3449
13. Ukkola O, Kervinen K, Salmela PI, Dickhoff KV, Laakso M, Kesaniemi YA. Apolipoprotein E phenotype is related to macro- and microangiopathy in patients with non-insulin dependent diabetes mellitus. Atherosclerosis 1993; 101: 9-15
14. Boize R, Benhamou P-Y, Corticelli P, Valenti K, Bosson J-L, Halimi S. ApoE polymorphism and albuminuria in diabetes mellitus: a role for LDL in the development of nephropathy in NIDDM? Nephrol Dial Transplant 1998; 13: 72-75
15. Horita K, Eto M, Makino I. Apolipoprotein E2, renal failure and lipid abnormalities in non-insulin dependent diabetes mellitus. Atherosclerosis 1994; 107: 203-211
16. Eto M, Horita K, Morikawa A, Nakata H, Okada M, Saito M, Nomura M, Abiko A, Iwashima Y, Ikoda A, Makini I. Increased frequency of apolipoprotein ε2 allele in non-insulin dependent diabetic (NIDDM) patients with nephropathy. Clin Genet 1995; 48: 288-292
17. Onuma T, Laffel LMB, Angelico C, Krolewski AS. Apolipoprotein E genotypes and risk of diabetic nephropathy. J Am Soc Nephrol 1996; 7: 1075-1078
18. Kimura H, Suzuki Y, Gejyo F, Karasawa R, Miyazaki R, Suzuki S, Arakawa M. Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM. Am J Kidney Dis 1998; 31: 666-673
19. Eto M, Watanabe K, Ishii K. A racial difference in apolipoprotein E allele frequences between the Japanese and Caucasian populations. Clin Genet 1986; 30: 422-427
20. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990; 31: 545-548
21. Diamond JR, Karnovsky MJ. Exacerbation of chronic aminonucleoside nephrosis by dietary cholesterol. Kidney Int 1987; 12: 671-677
22. Kasiske BL, O'Donnell MP, Cowardin W, Keane WF. Lipids and the kidney. Hypertension 1990; 15: 443-450
23. Suzaki K, Kobori S, Ueno S et al. Effect of plasma pheresis on familial type III hyperlipoproteinemia associated with glomerular lipidosis, nephrotic syndrome and diabetes mellitus. Atherosclerosis 1990; 80: 181-189
24. Okiwa S, Suzuki N, Sakuma E et al. Abnormal lipoprotein and apolipoprotein pattern in lipoprotein glomerulopathy. Am J Kidney Dis 1991; 18: 553-558
25. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992; 15: 815-819